Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 188

1.

The Capstone ePortfolio in an Undergraduate Public Health Program: Accreditation, Assessment, and Audience.

Harver A, Zuber PD, Bastian H.

Front Public Health. 2019 May 31;7:125. doi: 10.3389/fpubh.2019.00125. eCollection 2019.

2.

Economic and immunisation safety surveillance characteristics of countries implementing no-fault compensation programmes for vaccine injuries.

Mungwira RG, Maure CG, Zuber PLF.

Vaccine. 2019 Jul 18;37(31):4370-4375. doi: 10.1016/j.vaccine.2019.06.018. Epub 2019 Jun 15.

PMID:
31213377
3.

Pediatric Appropriate Evaluation Protocol for India (PAEP-India): Tool for Assessing Appropriateness of Pediatric Hospitalization.

Das MK, Arora NK, Poluru R, Seth A, Aggarwal A, Dubey AP, Goyal PC, Gathwala G, Malik A, Goel AK, Chakravarty A, Arya S, Upadhyay A, Gupta M, Mathew T, Pillai RK, Mathai J, Manivasagan S, Ramesh S, Aggarwal MK, Maure CG, Zuber PL.

Indian Pediatr. 2018 Dec 15;55(12):1041-1045.

4.

Reversible fold-switching controls the functional cycle of the antitermination factor RfaH.

Zuber PK, Schweimer K, Rösch P, Artsimovitch I, Knauer SH.

Nat Commun. 2019 Feb 11;10(1):702. doi: 10.1038/s41467-019-08567-6.

5.

Self-Managed Strength Training for Active Duty Military With a Knee Injury: A Randomized Controlled Pilot Trial.

Talbot Col Usafr Ret LA, Brede E, Price MN, Zuber PD, Metter EJ.

Mil Med. 2019 Jul 1;184(7-8):e174-e183. doi: 10.1093/milmed/usy347.

PMID:
30690578
6.

Mapping the landscape of global programmes to evaluate health interventions in pregnancy: the need for harmonised approaches, standards and tools.

Zuber PLF, Moran AC, Chou D, Renaud F, Halleux C, Peña-Rosas JP, Viswanathan K, Lackritz E, Jakob R, Mason E, Lamprianou S, Guillard-Maure C.

BMJ Glob Health. 2018 Oct 15;3(5):e001053. doi: 10.1136/bmjgh-2018-001053. eCollection 2018.

7.

Vaccine safety surveillance in pregnancy in low- and middle-income countries using GAIA case definitions: A feasibility assessment.

Stuurman AL, Riera M, Lamprianou S, Perez-Vilar S, Anderson SA, Mangtani P, Devlieger H, Verstraeten T, Zuber PLF, Guillard Maure C.

Vaccine. 2018 Oct 29;36(45):6736-6743. doi: 10.1016/j.vaccine.2018.09.033. Epub 2018 Sep 25.

8.

Using surveillance and economic data to make informed decisions about rotavirus vaccine introduction.

Cohen AL, Aliabadi N, Serhan F, Tate JE, Zuber P, Parashar UD.

Vaccine. 2018 Dec 14;36(51):7755-7758. doi: 10.1016/j.vaccine.2018.05.052. Epub 2018 Aug 18.

PMID:
30131194
9.

Structure and nucleic acid binding properties of KOW domains 4 and 6-7 of human transcription elongation factor DSIF.

Zuber PK, Hahn L, Reinl A, Schweimer K, Knauer SH, Gottesman ME, Rösch P, Wöhrl BM.

Sci Rep. 2018 Aug 3;8(1):11660. doi: 10.1038/s41598-018-30042-3.

10.

The universally-conserved transcription factor RfaH is recruited to a hairpin structure of the non-template DNA strand.

Zuber PK, Artsimovitch I, NandyMazumdar M, Liu Z, Nedialkov Y, Schweimer K, Rösch P, Knauer SH.

Elife. 2018 May 9;7. pii: e36349. doi: 10.7554/eLife.36349.

11.

Intussusception in Young Children: Protocol for Multisite Hospital Sentinel Surveillance in India.

Das MK, Arora NK, Bonhoeffer J, Zuber PLF, Maure CG.

Methods Protoc. 2018 Mar 22;1(2). pii: E11. doi: 10.3390/mps1020011.

12.

Use of a new global indicator for vaccine safety surveillance and trends in adverse events following immunization reporting 2000-2015.

Lei J, Balakrishnan MR, Gidudu JF, Zuber PLF.

Vaccine. 2018 Mar 14;36(12):1577-1582. doi: 10.1016/j.vaccine.2018.02.012. Epub 2018 Feb 14.

13.

Building capacity for active surveillance of vaccine adverse events in the Americas: A hospital-based multi-country network.

Bravo-Alcántara P, Pérez-Vilar S, Molina-León HF, Sturkenboom M, Black S, Zuber PLF, Maure C, Castro JL; L.A.N.V.A.P. (Latin American Network for VAccine Pharmacovigilance).

Vaccine. 2018 Jan 8;36(3):363-370. doi: 10.1016/j.vaccine.2017.04.069. Epub 2017 Aug 10.

PMID:
28803714
14.

Factors affecting the bacterial community composition and heterotrophic production of Columbia River estuarine turbidity maxima.

Herfort L, Crump BC, Fortunato CS, McCue LA, Campbell V, Simon HM, Baptista AM, Zuber P.

Microbiologyopen. 2017 Dec;6(6). doi: 10.1002/mbo3.522. Epub 2017 Aug 6.

15.

Operational lessons learned in conducting a multi-country collaboration for vaccine safety signal verification and hypothesis testing: The global vaccine safety multi country collaboration initiative.

Guillard-Maure C, Elango V, Black S, Perez-Vilar S, Castro JL, Bravo-Alcántara P, Molina-León HF, Weibel D, Sturkenboom M, Zuber PLF; WHO Global Vaccine Safety-Multi Country Collaboration.

Vaccine. 2018 Jan 8;36(3):355-362. doi: 10.1016/j.vaccine.2017.07.085. Epub 2017 Aug 2.

PMID:
28780118
16.

The public health value of vaccines beyond efficacy: methods, measures and outcomes.

Wilder-Smith A, Longini I, Zuber PL, Bärnighausen T, Edmunds WJ, Dean N, Spicher VM, Benissa MR, Gessner BD.

BMC Med. 2017 Jul 26;15(1):138. doi: 10.1186/s12916-017-0911-8.

17.

Enhancing global vaccine pharmacovigilance: Proof-of-concept study on aseptic meningitis and immune thrombocytopenic purpura following measles-mumps containing vaccination.

Perez-Vilar S, Weibel D, Sturkenboom M, Black S, Maure C, Castro JL, Bravo-Alcántara P, Dodd CN, Romio SA, de Ridder M, Nakato S, Molina-León HF, Elango V, Zuber PLF; WHO Global Vaccine Safety-Multi Country Collaboration.

Vaccine. 2018 Jan 8;36(3):347-354. doi: 10.1016/j.vaccine.2017.05.012. Epub 2017 May 27.

18.

Exploring the Amino Acid Residue Requirements of the RNA Polymerase (RNAP) α Subunit C-Terminal Domain for Productive Interaction between Spx and RNAP of Bacillus subtilis.

Birch CA, Davis MJ, Mbengi L, Zuber P.

J Bacteriol. 2017 Jun 27;199(14). pii: e00124-17. doi: 10.1128/JB.00124-17. Print 2017 Jul 15.

19.

Use of Highly Specific Molecular Markers Reveals Positive Correlation between Abundances of Mesodinium cf. major and Its Preferred Prey, Teleaulax amphioxeia, During Red Water Blooms in the Columbia River Estuary.

Herfort L, Maxey K, Voorhees I, Simon HM, Grobler K, Peterson TD, Zuber P.

J Eukaryot Microbiol. 2017 Nov;64(6):740-755. doi: 10.1111/jeu.12407. Epub 2017 Apr 7.

PMID:
28258655
20.

Global alignment of immunization safety assessment in pregnancy - The GAIA project.

Bonhoeffer J, Kochhar S, Hirschfeld S, Heath PT, Jones CE, Bauwens J, Honrado Á, Heininger U, Muñoz FM, Eckert L, Steinhoff M, Black S, Padula M, Sturkenboom M, Buttery J, Pless R, Zuber P; GAIA project participants.

Vaccine. 2016 Dec 1;34(49):5993-5997. doi: 10.1016/j.vaccine.2016.07.006. Epub 2016 Oct 14.

21.
22.

Guideline for collection, analysis and presentation of safety data in clinical trials of vaccines in pregnant women.

Jones CE, Munoz FM, Spiegel HM, Heininger U, Zuber PL, Edwards KM, Lambach P, Neels P, Kohl KS, Gidudu J, Hirschfeld S, Oleske JM, Khuri-Bulos N, Bauwens J, Eckert LO, Kochhar S, Bonhoeffer J, Heath PT; Brighton Collaboration Immunization in Pregnancy Working Group.

Vaccine. 2016 Dec 1;34(49):5998-6006. doi: 10.1016/j.vaccine.2016.07.032. Epub 2016 Jul 29.

23.

Fast-tumbling bicelles constructed from native Escherichia coli lipids.

Liebau J, Pettersson P, Zuber P, Ariöz C, Mäler L.

Biochim Biophys Acta. 2016 Sep;1858(9):2097-2105. doi: 10.1016/j.bbamem.2016.06.008. Epub 2016 Jun 15.

24.

Contributions and challenges for worldwide vaccine safety: The Global Advisory Committee on Vaccine Safety at 15 years.

Asturias EJ, Wharton M, Pless R, MacDonald NE, Chen RT, Andrews N, Salisbury D, Dodoo AN, Hartigan-Go K, Zuber PL.

Vaccine. 2016 Jun 17;34(29):3342-9. doi: 10.1016/j.vaccine.2016.05.018. Epub 2016 May 16. Review.

25.

A global survey of adverse event following immunization surveillance systems for pregnant women and their infants.

Cassidy C, MacDonald NE, Steenbeek A, Ortiz JR, Zuber PL, Top KA.

Hum Vaccin Immunother. 2016 Aug 2;12(8):2010-2016. Epub 2016 May 9.

26.

Enhancing Vaccine Safety Capacity Globally: A Lifecycle Perspective.

Chen RT, Shimabukuro TT, Martin DB, Zuber PL, Weibel DM, Sturkenboom M.

Am J Prev Med. 2015 Dec;49(6 Suppl 4):S364-76. doi: 10.1016/j.amepre.2015.09.009. Review.

PMID:
26590436
27.

Active Surveillance for Adverse Events After a Mass Vaccination Campaign With a Group A Meningococcal Conjugate Vaccine (PsA-TT) in Mali.

Vannice KS, Keita M, Sow SO, Durbin AP, Omer SB, Moulton LH, Yaméogo TM, Zuber PL, Onwuchekwa U, Sacko M, Diomandé FV, Halsey NA.

Clin Infect Dis. 2015 Nov 15;61 Suppl 5:S493-500. doi: 10.1093/cid/civ497.

28.

The Safety of PsA-TT in Pregnancy: An Assessment Performed Within the Navrongo Health and Demographic Surveillance Site in Ghana.

Wak G, Williams J, Oduro A, Maure C, Zuber PL, Black S.

Clin Infect Dis. 2015 Nov 15;61 Suppl 5:S489-92. doi: 10.1093/cid/civ625.

29.

Lessons Learned From Enhancing Vaccine Pharmacovigilance Activities During PsA-TT Introduction in African Countries, 2010-2013.

Diomandé FV, Yaméogo TM, Vannice KS, Preziosi MP, Viviani S, Ouandaogo CR, Keita M, Djingarey MH, Mbakuliyemo N, Akanmori BD, Sow SO, Zuber PL.

Clin Infect Dis. 2015 Nov 15;61 Suppl 5:S459-66. doi: 10.1093/cid/civ599.

30.

Enhancing vaccine safety capacity globally: A lifecycle perspective.

Chen RT, Shimabukuro TT, Martin DB, Zuber PL, Weibel DM, Sturkenboom M.

Vaccine. 2015 Nov 27;33 Suppl 4:D46-54. doi: 10.1016/j.vaccine.2015.06.073. Epub 2015 Oct 1. Review.

31.
32.

The Global Vaccine Safety Initiative: enhancing vaccine pharmacovigilance capacity at country level.

Maure CG, Dodoo AN, Bonhoeffer J, Zuber PL.

Bull World Health Organ. 2014 Sep 1;92(9):695-6. doi: 10.2471/BLT.14.138875. Epub 2014 Jul 31. No abstract available.

33.

Safety of immunization during pregnancy: a review of the evidence of selected inactivated and live attenuated vaccines.

Keller-Stanislawski B, Englund JA, Kang G, Mangtani P, Neuzil K, Nohynek H, Pless R, Lambach P, Zuber P.

Vaccine. 2014 Dec 12;32(52):7057-64. doi: 10.1016/j.vaccine.2014.09.052. Epub 2014 Oct 5. Review.

PMID:
25285883
34.

spxA2, encoding a regulator of stress resistance in Bacillus anthracis, is controlled by SaiR, a new member of the Rrf2 protein family.

Nakano MM, Kominos-Marvell W, Sane B, Nader YM, Barendt SM, Jones MB, Zuber P.

Mol Microbiol. 2014 Nov;94(4):815-27. doi: 10.1111/mmi.12798. Epub 2014 Oct 16.

35.

Discovery of a Katablepharis sp. in the Columbia River estuary that is abundant during the spring and bears a unique large ribosomal subunit sequence element.

Kahn P, Herfort L, Peterson TD, Zuber P.

Microbiologyopen. 2014 Oct;3(5):764-76. doi: 10.1002/mbo3.206. Epub 2014 Aug 28.

36.

Adaptor bypass mutations of Bacillus subtilis spx suggest a mechanism for YjbH-enhanced proteolysis of the regulator Spx by ClpXP.

Chan CM, Hahn E, Zuber P.

Mol Microbiol. 2014 Aug;93(3):426-38. doi: 10.1111/mmi.12671. Epub 2014 Jul 10.

37.

Assessment of causality of individual adverse events following immunization (AEFI): a WHO tool for global use.

Tozzi AE, Asturias EJ, Balakrishnan MR, Halsey NA, Law B, Zuber PL.

Vaccine. 2013 Oct 17;31(44):5041-6. doi: 10.1016/j.vaccine.2013.08.087. Epub 2013 Sep 8.

PMID:
24021304
38.

Transcriptomic and phenotypic analysis of paralogous spx gene function in Bacillus anthracis Sterne.

Barendt S, Lee H, Birch C, Nakano MM, Jones M, Zuber P.

Microbiologyopen. 2013 Aug;2(4):695-714. doi: 10.1002/mbo3.109. Epub 2013 Jul 22.

40.

International collaboration to assess the risk of Guillain Barré Syndrome following Influenza A (H1N1) 2009 monovalent vaccines.

Dodd CN, Romio SA, Black S, Vellozzi C, Andrews N, Sturkenboom M, Zuber P, Hua W, Bonhoeffer J, Buttery J, Crawford N, Deceuninck G, de Vries C, De Wals P, Gutierrez-Gimeno MV, Heijbel H, Hughes H, Hur K, Hviid A, Kelman J, Kilpi T, Chuang SK, Macartney K, Rett M, Lopez-Callada VR, Salmon D, Gimenez-Sanchez F, Sanz N, Silverman B, Storsaeter J, Thirugnanam U, van der Maas N, Yih K, Zhang T, Izurieta H; Global H1N1 GBS Consortium.

Vaccine. 2013 Sep 13;31(40):4448-58. doi: 10.1016/j.vaccine.2013.06.032. Epub 2013 Jun 14.

PMID:
23770307
41.

Roadmap for the international collaborative epidemiologic monitoring of safety and effectiveness of new high priority vaccines.

Izurieta HS, Zuber P, Bonhoeffer J, Chen RT, Sankohg O, Laserson KF, Sturkenboom M, Loucq C, Weibel D, Dodd C, Black S.

Vaccine. 2013 Aug 2;31(35):3623-7. doi: 10.1016/j.vaccine.2013.05.027. Epub 2013 May 21.

PMID:
23707171
42.

Effective vaccine safety systems in all countries: a challenge for more equitable access to immunization.

Amarasinghe A, Black S, Bonhoeffer J, Carvalho SM, Dodoo A, Eskola J, Larson H, Shin S, Olsson S, Balakrishnan MR, Bellah A, Lambach P, Maure C, Wood D, Zuber P, Akanmori B, Bravo P, Pombo M, Langar H, Pfeifer D, Guichard S, Diorditsa S, Hossain MS, Sato Y.

Vaccine. 2013 Apr 18;31 Suppl 2:B108-14. doi: 10.1016/j.vaccine.2012.10.119. Review.

PMID:
23598471
43.

Ubiquitous dissolved inorganic carbon assimilation by marine bacteria in the Pacific Northwest coastal ocean as determined by stable isotope probing.

DeLorenzo S, Bräuer SL, Edgmont CA, Herfort L, Tebo BM, Zuber P.

PLoS One. 2012;7(10):e46695. doi: 10.1371/journal.pone.0046695. Epub 2012 Oct 3.

44.

Current status and future directions of post-marketing vaccine safety monitoring with focus on USA and Europe.

Bonhoeffer J, Black S, Izurieta H, Zuber P, Sturkenboom M.

Biologicals. 2012 Sep;40(5):393-7. doi: 10.1016/j.biologicals.2012.07.007. Epub 2012 Aug 17. Review. Erratum in: Biologicals. 2013 Mar;41(2):128.

PMID:
22902972
45.

Monitoring adverse events following immunization with a new conjugate vaccine against group A meningococcus in Niger, September 2010.

Chaibou MS, Bako H, Salisou L, Yaméogo TM, Sambo M, Kim SH, Djingarey MH, Zuber PL, Perea WA, Pezzoli L.

Vaccine. 2012 Jul 27;30(35):5229-34. doi: 10.1016/j.vaccine.2012.06.006. Epub 2012 Jun 16.

PMID:
22709955
46.

Effectively introducing a new meningococcal A conjugate vaccine in Africa: the Burkina Faso experience.

Djingarey MH, Barry R, Bonkoungou M, Tiendrebeogo S, Sebgo R, Kandolo D, Lingani C, Preziosi MP, Zuber PL, Perea W, Hugonnet S, Dellepiane de Rey Tolve N, Tevi-Benissan C, Clark TA, Mayer LW, Novak R, Messonier NE, Berlier M, Toboe D, Nshimirimana D, Mihigo R, Aguado T, Diomandé F, Kristiansen PA, Caugant DA, Laforce FM.

Vaccine. 2012 May 30;30 Suppl 2:B40-5. doi: 10.1016/j.vaccine.2011.12.073. Review.

PMID:
22607898
47.

Research priorities regarding rotavirus vaccine and intussusception: a meeting summary.

Tate JE, Steele AD, Bines JE, Zuber PL, Parashar UD.

Vaccine. 2012 Apr 27;30 Suppl 1:A179-84. doi: 10.1016/j.vaccine.2011.08.110.

PMID:
22520129
48.

Geobacillus thermodenitrificans YjbH recognizes the C-terminal end of Bacillus subtilis Spx to accelerate Spx proteolysis by ClpXP.

Chan CM, Garg S, Lin AA, Zuber P.

Microbiology. 2012 May;158(Pt 5):1268-78. doi: 10.1099/mic.0.057661-0. Epub 2012 Feb 16.

49.

Evidence that a single monomer of Spx can productively interact with RNA polymerase in Bacillus subtilis.

Lin AA, Zuber P.

J Bacteriol. 2012 Apr;194(7):1697-707. doi: 10.1128/JB.06660-11. Epub 2012 Feb 3.

50.

Adverse events following immunization during mass vaccination campaigns at first introduction of a meningococcal A conjugate vaccine in Burkina Faso, 2010.

Ouandaogo CR, Yaméogo TM, Diomandé FV, Sawadogo C, Ouédraogo B, Ouédraogo-Traoré R, Pezzoli L, Djingarey MH, Mbakuliyemo N, Zuber PL.

Vaccine. 2012 May 30;30 Suppl 2:B46-51. doi: 10.1016/j.vaccine.2011.12.112. Epub 2012 Jan 9.

PMID:
22230584

Supplemental Content

Support Center